Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Recurrent Glioblastoma Multiforme Treatment Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 AU-105
      • 1.3.3 Axitinib
      • 1.3.4 AXL-1717
      • 1.3.5 AZD-7451
      • 1.3.6 Others
    • 1.4 Market Segment by Application
      • 1.4.1 Global Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2019-2025)
      • 1.4.2 Hospital
      • 1.4.3 Clinic
      • 1.4.4 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size
      • 2.1.1 Global Recurrent Glioblastoma Multiforme Treatment Revenue 2014-2025
      • 2.1.2 Global Recurrent Glioblastoma Multiforme Treatment Sales 2014-2025
    • 2.2 Recurrent Glioblastoma Multiforme Treatment Growth Rate by Regions
      • 2.2.1 Global Recurrent Glioblastoma Multiforme Treatment Sales by Regions 2014-2019
      • 2.2.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Recurrent Glioblastoma Multiforme Treatment Sales by Manufacturers
      • 3.1.1 Recurrent Glioblastoma Multiforme Treatment Sales by Manufacturers 2014-2019
      • 3.1.2 Recurrent Glioblastoma Multiforme Treatment Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Recurrent Glioblastoma Multiforme Treatment Revenue by Manufacturers (2014-2019)
      • 3.2.2 Recurrent Glioblastoma Multiforme Treatment Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Recurrent Glioblastoma Multiforme Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.3 Recurrent Glioblastoma Multiforme Treatment Price by Manufacturers
    • 3.4 Key Manufacturers Recurrent Glioblastoma Multiforme Treatment Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Recurrent Glioblastoma Multiforme Treatment Market
    • 3.6 Key Manufacturers Recurrent Glioblastoma Multiforme Treatment Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 AU-105 Sales and Revenue (2014-2019)
      • 4.1.2 Axitinib Sales and Revenue (2014-2019)
      • 4.1.3 AXL-1717 Sales and Revenue (2014-2019)
      • 4.1.4 AZD-7451 Sales and Revenue (2014-2019)
      • 4.1.5 Others Sales and Revenue (2014-2019)
    • 4.2 Global Recurrent Glioblastoma Multiforme Treatment Sales Market Share by Type
    • 4.3 Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Type
    • 4.4 Recurrent Glioblastoma Multiforme Treatment Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Recurrent Glioblastoma Multiforme Treatment Sales by Application

    6 United States

    • 6.1 United States Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Company
    • 6.2 United States Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Type
    • 6.3 United States Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Application

    7 European Union

    • 7.1 European Union Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Company
    • 7.2 European Union Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Type
    • 7.3 European Union Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Application

    8 China

    • 8.1 China Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Company
    • 8.2 China Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Type
    • 8.3 China Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Company
    • 9.2 Rest of World Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Type
    • 9.3 Rest of World Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Application
    • 9.4 Rest of World Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Countries
      • 9.4.1 Rest of World Recurrent Glioblastoma Multiforme Treatment Sales by Countries
      • 9.4.2 Rest of World Recurrent Glioblastoma Multiforme Treatment Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Boehringer Ingelheim GmbH
      • 10.1.1 Boehringer Ingelheim GmbH Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Recurrent Glioblastoma Multiforme Treatment
      • 10.1.4 Recurrent Glioblastoma Multiforme Treatment Product Introduction
      • 10.1.5 Boehringer Ingelheim GmbH Recent Development
    • 10.2 Boston Biomedical, Inc.
      • 10.2.1 Boston Biomedical, Inc. Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Recurrent Glioblastoma Multiforme Treatment
      • 10.2.4 Recurrent Glioblastoma Multiforme Treatment Product Introduction
      • 10.2.5 Boston Biomedical, Inc. Recent Development
    • 10.3 Bristol-Myers Squibb Company
      • 10.3.1 Bristol-Myers Squibb Company Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Recurrent Glioblastoma Multiforme Treatment
      • 10.3.4 Recurrent Glioblastoma Multiforme Treatment Product Introduction
      • 10.3.5 Bristol-Myers Squibb Company Recent Development
    • 10.4 Cantex Pharmaceuticals, Inc.
      • 10.4.1 Cantex Pharmaceuticals, Inc. Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Recurrent Glioblastoma Multiforme Treatment
      • 10.4.4 Recurrent Glioblastoma Multiforme Treatment Product Introduction
      • 10.4.5 Cantex Pharmaceuticals, Inc. Recent Development
    • 10.5 Cavion LLC
      • 10.5.1 Cavion LLC Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Recurrent Glioblastoma Multiforme Treatment
      • 10.5.4 Recurrent Glioblastoma Multiforme Treatment Product Introduction
      • 10.5.5 Cavion LLC Recent Development
    • 10.6 Celldex Therapeutics, Inc.
      • 10.6.1 Celldex Therapeutics, Inc. Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Recurrent Glioblastoma Multiforme Treatment
      • 10.6.4 Recurrent Glioblastoma Multiforme Treatment Product Introduction
      • 10.6.5 Celldex Therapeutics, Inc. Recent Development
    • 10.7 Coherus BioSciences, Inc.
      • 10.7.1 Coherus BioSciences, Inc. Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Recurrent Glioblastoma Multiforme Treatment
      • 10.7.4 Recurrent Glioblastoma Multiforme Treatment Product Introduction
      • 10.7.5 Coherus BioSciences, Inc. Recent Development
    • 10.8 Cortice Biosciences, Inc.
      • 10.8.1 Cortice Biosciences, Inc. Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Recurrent Glioblastoma Multiforme Treatment
      • 10.8.4 Recurrent Glioblastoma Multiforme Treatment Product Introduction
      • 10.8.5 Cortice Biosciences, Inc. Recent Development
    • 10.9 Eisai
      • 10.9.1 Eisai Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Recurrent Glioblastoma Multiforme Treatment
      • 10.9.4 Recurrent Glioblastoma Multiforme Treatment Product Introduction
      • 10.9.5 Eisai Recent Development
    • 10.10 Eli Lilly and Company
      • 10.10.1 Eli Lilly and Company Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Recurrent Glioblastoma Multiforme Treatment
      • 10.10.4 Recurrent Glioblastoma Multiforme Treatment Product Introduction
      • 10.10.5 Eli Lilly and Company Recent Development
    • 10.11 EnGeneIC Ltd
    • 10.12 ERC Belgium SA
    • 10.13 GenSpera, Inc.
    • 10.14 Genzyme Corporation
    • 10.15 GW Pharmaceuticals Plc
    • 10.16 ImmunoCellular Therapeutics, Ltd.

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Recurrent Glioblastoma Multiforme Treatment Sales Channels
      • 11.2.2 Recurrent Glioblastoma Multiforme Treatment Distributors
    • 11.3 Recurrent Glioblastoma Multiforme Treatment Customers

    12 Market Forecast

    • 12.1 Global Recurrent Glioblastoma Multiforme Treatment Sales and Revenue Forecast 2019-2025
    • 12.2 Global Recurrent Glioblastoma Multiforme Treatment Sales Forecast by Type
    • 12.3 Global Recurrent Glioblastoma Multiforme Treatment Sales Forecast by Application
    • 12.4 Recurrent Glioblastoma Multiforme Treatment Forecast by Regions
      • 12.4.1 Global Recurrent Glioblastoma Multiforme Treatment Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of Recurrent Glioblastoma Multiforme Treatment is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Recurrent Glioblastoma Multiforme Treatment.

      This report studies the global market size of Recurrent Glioblastoma Multiforme Treatment, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Recurrent Glioblastoma Multiforme Treatment sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Boehringer Ingelheim GmbH
      Boston Biomedical, Inc.
      Bristol-Myers Squibb Company
      Cantex Pharmaceuticals, Inc.
      Cavion LLC
      Celldex Therapeutics, Inc.
      Coherus BioSciences, Inc.
      Cortice Biosciences, Inc.
      Eisai
      Eli Lilly and Company
      EnGeneIC Ltd
      ERC Belgium SA
      GenSpera, Inc.
      Genzyme Corporation
      GW Pharmaceuticals Plc
      ImmunoCellular Therapeutics, Ltd.

      Market Segment by Product Type
      AU-105
      Axitinib
      AXL-1717
      AZD-7451
      Others

      Market Segment by Application
      Hospital
      Clinic
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Recurrent Glioblastoma Multiforme Treatment status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Recurrent Glioblastoma Multiforme Treatment manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Recurrent Glioblastoma Multiforme Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now